NCT06985602招募中2 期
Adebrelimab Combined With Chemoradiotherapy Followed by Surgery for Locally Advanced or Limited Metastatic Gastric/ Esophagogastric Junction Adenocarcinoma.
Jiangsu Cancer Institute & Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年5月16日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Treatment Safety
研究概览
简要总结
Gastric cancer is one of the most common and deadly cancers globally, characterized by a poor prognosis. Approximately 70% of patients are diagnosed at an advanced stage, and the 5-year survival rate is only around 10%. While advancements in targeted therapies and immunotherapy have improved treatment efficacy and extended survival, advanced gastric and gastroesophageal junction adenocarcinomas remain incurable. Subgroup analyses indicate that patients with limited metastases, such as liver oligometastasis or retroperitoneal lymph node metastasis, may benefit more from conversion therapy. However, current guidelines do not recommend specific treatment protocols for gastric cancer with limited metastasis. Immunotherapy has shown moderate efficacy in selected patients with advanced gastric adenocarcinoma. Additionally, low-dose radiotherapy (LDRT) may synergistically enhance antitumor responses when combined with immunotherapy. This Phase II trial aims to evaluate the safety and efficacy of combining Adebrelimab, chemotherapy, and LDRT before surgery in treating adult patients with gastric or gastroesophageal junction adenocarcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed esophagogastric junction (EGJ)/gastric adenocarcinoma.
- •Patients with locally advanced disease (AJCC staging T4b or N2 fusion metastasis) or limited metastasis confirmed by endoscopy, CT, MRI, or PET/CT scans, and multidisciplinary team (MDT) discussion.
- •From a medical and surgical technical perspective, the primary lesion and surrounding abdominal lymph nodes are assessed as potentially resectable; limited metastatic lesions are evaluated by MDT for resectability or for the possibility of achieving curative treatment through other local treatment methods (such as local radiotherapy or radiofrequency ablation).
- •Exclusion of peritoneal metastasis.
- •Adequate hematological function: Neutrophil count ≥ 1.5 × 109/L, Platelets ≥ 100 × 109/L and Hemoglobin ≥90g/L.
- •Adequate liver function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 × ULN in the absence of liver metastases, or < 5 × ULN in case of liver metastases. ALP ≤ 2.5 × upper limit of normal (ULN); ALB ≥30g/L.
- •Adequate renal function: Serum creatinine ≤ 1.5 x ULN, and creatinine clearance ≥ 60 ml/min.
- •Adequate coagulation function: INR/PT≤ 1.5 x ULN, aPTT≤ 1.5 x ULN.
- •No serious concomitant disease that will threaten the survival of patients to less than 5 years.
- •Male or female. Age ≥ 18 years and ≤80 years.
- •Written (signed) informed consent.
- •Good compliance with the study procedures, including lab and auxiliary examination and treatment.
- •Female patients should not be pregnant or breast feeding.
排除标准
- •Non-adenocarcinoma histology of gastric/esophagogastric junction tumors, such as squamous cell carcinoma or neuroendocrine carcinoma.
- •The primary lesion is considered unresectable from a medical or surgical technical perspective.
- •Imaging diagnosis indicates widespread metastasis (metastasis that does not meet the criteria for limited metastasis as defined above is considered widespread metastasis).
- •Peripheral neuropathy of grade ≥
- •Poor nutritional status, BMI <18.5 kg/m², or PG-SGA score ≥
- •Underwent major surgery or suffered a severe injury within 4 weeks prior to the first dose of the investigational drug.
- •Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
- •Received any investigational drug within 4 weeks prior to the first dose of the study drug.
- •Required systemic treatment with corticosteroids (daily >10 mg prednisone equivalent) or other immunosuppressive agents within 2 weeks prior to the first dose of the investigational drug.
- •Received an anti-tumor vaccine or live vaccine within 4 weeks before the first dose of the study drug.
- •Diagnosed with any active autoimmune disease or a history of autoimmune diseases.
- •History of immunodeficiency, including a positive HIV test, any acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation.
- •Any condition within 14 days prior to treatment requiring systemic corticosteroid therapy (dose>10mg/day of prednisone or equivalent) or other immunosuppressive treatments.
- •Presence of uncontrolled cardiac symptoms or conditions, such as:
- •NYHA Class II or higher heart failure
- •Unstable angina
- •Myocardial infarction within the past year
- •Clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention.
- •Severe infection within 4 weeks prior to the first dose, including pneumonia requiring hospitalization, bacteremia, or infectious complications.
- •History of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, or other uncontrolled acute pulmonary diseases.
- •Active pulmonary tuberculosis infection diagnosed by history or CT scan, or a history of active tuberculosis infection within the past year, or a history of untreated active tuberculosis infection more than one year ago.
- •Active hepatitis B or hepatitis C.
- •Laboratory abnormalities of sodium, potassium, or calcium greater than Grade 1 within 2 weeks before enrollment that cannot be corrected with treatment.
- •Known allergy to monoclonal antibodies, any PD-1 components, paclitaxel, capecitabine, or any components used in their formulations.
- •Pregnant or breastfeeding women, or women of childbearing potential who are unwilling or unable to use effective contraception.
研究组 & 干预措施
Arm 1: Adebrelimab Combined with Chemoradiotherapy Followed by Surgery
Experimental
干预措施: Arm 1: Adebrelimab Combined with Chemoradiotherapy Followed by Surgery (Combination Product)
结局指标
主要结局
Treatment Safety
时间窗: From enrollment until the end of treatment, assessed up to 18 months.
Treatment-related adverse events will be categorized by severity and relationship to treatment. Descriptive statistics will be used to summarize the frequency and types.
次要结局
- R0 Rate(From the completion of conversion therapy until surgery, assessed within 8 weeks.. following treatment completion)
- Pathologic complete response(From the completion of conversion therapy until surgery, assessed within 8 weeks following treatment completion)
- Progression-Free Survival(From enrollment until tumor progression or death from any cause, whichever occurs first, assessed up to 2 years)
- Overall Survival(From enrollment until death from any cause, assessed up to 3 years.)
研究者
Cheng Chen
Doctor
Jiangsu Cancer Institute & Hospital
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Combination of checkpoint inhibitor and radiotherapy for re-current gastric cancer after initial treatment with standard therapy.Gastric cancerJPRN-jRCTs021180002Kono Koji41
招募中
1 期
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic CancerAdebrelimab (SHR-1316)Metastatic Pancreatic CancerDecitabineNCT06454448Tianjin Medical University Cancer Institute and Hospital20
已完成
2 期
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric CancerStomach NeoplasmsNCT04694183Quan Wang37
已完成
2 期
Chemotherapy Combined With Apatinib and PD-1 AntibodyGastric CancerNCT05025033Tianjin Medical University Cancer Institute and Hospital30
已完成
2 期
Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJGastric or Gastroesophageal Junction AdenocarcinomaNCT05941481Jiangsu Cancer Institute & Hospital21